NCT04343092View on ClinicalTrials.gov

Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

April 18, 2020

Primary Completion Date

May 31, 2020

Study Completion Date

June 1, 2020

Conditions
COVID 19
Interventions
DRUG

Ivermectin (IVM)

Ivermectin 0.2 mg /kg (single dose at once =2 tablets of 6mg/weekly

Trial Locations (1)

964

General Directorate of Medical City, Baghdad

All Listed Sponsors
lead

University of Baghdad

OTHER

NCT04343092 - Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management | Biotech Hunter | Biotech Hunter